DALLAS, Sept. 21, 2026 /PRNewswire/ -- Solidion Technology, Inc. (NASDAQ: STI) ("Solidion Technology" or "the Company"), an advanced battery technology solutions provider, today announced that its Chairman and CEO, Jaymes Winters has increased his holdings with the purchase of 984 shares at $7.11 per share, bringing his total holding to 4,709 shares, which is 0.05% of issued share capital.

Purchase of Shares by CFO Vlad Prantsevich

Solidion Technologies also announced today that its CFO Vlad Prantsevich has increased his holdings with the purchase of 1,030 shares at $7.13 per share, bringing his total holding to 3,455 shares, which is 0.04% of issued share capital.

Purchase of Shares by Board Member Karin-Joyce Tjon

Solidion Technologies also announced today that its Board Member Karin-Joyce Tjon has increased her holdings with the purchase of 5,000 shares at $7.20 per share, bringing her total holding to 17,853 shares, which is 0.20% of issued share capital.

About Solidion Technology, Inc.

Headquartered in Dallas, Texas with pilot production facilities in Dayton, Ohio, Solidion's (NASDAQ: STI) core business includes manufacturing of battery materials and components, as well as development and production of next-generation batteries for energy storage systems, including UPS systems serving the artificial intelligence (AI) data center market and electric vehicles for ground, aerospace, and sea transportation. Solidion holds a portfolio of over 385 patents, covering innovations such as high-capacity, silane gas free and graphene-enabled silicon anodes, biomass-based graphite, advanced lithium-sulfur and lithium-metal technologies.

For more information, please visit www.solidiontech.com or contact Investor Relations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solidion Technology Inc., (NASDAQ: STI) (the "Company," "Solidion," "we," "our" or "us") desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words "forecasts" "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

Please follow us on:

LinkedIn: https://www.linkedin.com/company/solidion-tech

X: https://x.com/solidiontech?lang=en

SOURCE Solidion Technology, Inc.

Share this article

U.S. Army aviation and defense leader joins Quantum Systems Inc. to advance strategic growth and deepen engagement across the U.S. and the Americas.

WASHINGTON, Sept. 21, 2026 /PRNewswire/ -- Quantum-Systems Inc., the U.S. subsidiary of Quantum Systems Group, today announced the appointment of Raymond Santiago as Vice President of Growth & Strategic Engagement, The Americas. In this role, Santiago will lead strategic growth and engagement efforts across the United States and the broader Americas, strengthening relationships with defense and security stakeholders and aligning Quantum Systems' autonomous systems portfolio with evolving operational and acquisition priorities.

Santiago brings extensive experience in U.S. Army aviation, defense modernization and transformation, strategic integration, and capability development across complex national security environments. Throughout his career, he has worked at the intersection of emerging technologies, operational requirements, and acquisition priorities, with significant experience advising and engaging senior leaders across the Department of War and broader national security community.

Born in Puerto Rico, Santiago brings a personal connection to the region alongside decades of aviation and defense experience. His role will extend across the Americas, with a focus on strengthening regional partnerships and supporting aviation modernization throughout Latin America.

A career Army Aviator, Santiago's leadership experience spans operational command, multinational deployments, defense policy, and senior Pentagon assignments. His career culminated in leadership of Army aviation modernization, operations, and readiness efforts across a portfolio of more than 4,000 aircraft. He has also played a key role in advancing Future Vertical Lift, autonomous systems integration, aviation modernization, and transformational force design while working across the U.S. Army, Department of War, Department of State, and U.S. embassies abroad.

In his new role, Santiago will apply his operational and strategic experience to support Quantum Systems' continued growth across the Americas. He will focus on strengthening senior-level relationships across U.S. and regional defense and security communities, connecting operational needs with emerging technologies and acquisition pathways, and helping translate customer requirements into mission-relevant capabilities.

"Ray brings a rare combination of operational experience, strategic perspective, and a deep understanding of how emerging technologies move from concept to operational capability," said Dave Sharpin, CEO of Quantum-Systems Inc. "His leadership will strengthen our engagement with customers and partners not only in the United States, but throughout the Americas, as we continue expanding our ability to support evolving defense and security requirements across the region."

Santiago holds advanced degrees in National Security and Resource Strategy, Strategic Information and Cyberspace Studies, and Public Administration, including education from National Defense University. He is a Distinguished Graduate of National Defense University and a U.S. Army Aviator and Instructor Pilot, with additional executive education in data-driven leadership through Carnegie Mellon University and artificial intelligence through the University of Maryland's Robert H. Smith School of Business.

"Joining Quantum Systems gives me the opportunity to bring together two things that are deeply meaningful to me: advancing the future of autonomous defense operations and reconnecting with the region where my own story began," said Raymond Santiago, Vice President of Growth & Strategic Engagement, The Americas, Quantum-Systems Inc. "I'm especially proud to have the opportunity to strengthen relationships across the Americas and help advance aviation modernization throughout Latin America. I look forward to working alongside our customers and partners to understand their operational needs and help translate emerging autonomous technologies into capabilities that make a meaningful difference."

Media Contact

Media & Communications Department

About Quantum Systems Inc.

Quantum-Systems Inc. is the U.S. subsidiary of the Quantum Systems Group and forms a globalized, high-tech company specializing in unmanned systems. The company develops integrated hardware, software, and AI systems that deliver operational data in real time and enable informed decision-making across multiple domains. All core technologies are developed in-house and stand for technological excellence, scalability, and sovereignty in the global dual-use market.

SOURCE Quantum-Systems Inc.

Share this article

SINGAPORE, Sept. 21, 2026 /PRNewswire/ --WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today held a grand GMP release ceremony for its Singapore manufacturing site at Tuas Biomedical Park. From announcing the new site in March 2024 to achieving GMP release of the BCM3 antibody intermediate and conjugated drug substance dual-function production line and the DP4 facility in August 2026, this important milestone was reached in only two and a half years. It marks the transition of WuXi XDC's "Global Dual-Sourcing" strategy from blueprint to reality, opening a new chapter in empowering more global clients to accelerate commercial manufacturing.

At the beginning of the event, Dr. Jimmy Li, CEO of WuXi XDC, delivered opening remarks. He noted that the successful GMP release of the company's first overseas manufacturing site is a key step in WuXi XDC's global manufacturing footprint. Leveraging a globally leading quality system, cutting-edge innovation, and operational excellence, the company will continue to enhance the resilience and diversification of its supply system. The Singapore site will form a global collaborative network with sites in Wuxi, Shanghai, Hefei, and Suzhou, continuing to provide clients with end-to-end, one-stop CRDMO solutions for bioconjugates.

In her opening remarks at the event, Ms. Cindy Koh, Executive Vice President of the Singapore Economic Development Board (EDB) congratulated WuXi XDC for the GMP release of its Singapore site. She highlighted how the investment strengthens Singapore's capabilities in manufacturing complex new modalities and reflects WuXi XDC's confidence in Singapore as a trusted hub for biopharmaceutical manufacturing.

As a strategic partner of WuXi XDC, Mr. Li Daoquan, CEO of Morimatsu Pharmadule(China), was also invited to share his thoughts, recalling the efficient collaboration and outstanding execution between the two parties in the construction of the modular factory.

Following the speeches, the ribbon-cutting ceremony for the WuXi XDC Singapore site was held. Ms. Cindy Koh, Executive Vice President of EDB; Ms. Christine Wong, Assistant CEO (Cluster Group) of JTC Corporation; Dr. Jimmy Li, CEO of WuXi XDC; Mr. Jerry Zhang, COO of WuXi XDC; Dr. Marie Zhu, CTO of WuXi XDC; Dr. Hu Jun, Head of APAC Business Development & Global Commercial Operations and Singapore Site Management of WuXi XDC; and Dr. Zhang Xiao, Head of Conjugated Drug Substance and Singapore Site Production of WuXi XDC; Dr. JJ Luo, Head of Bioconjugate Drug Products Development of WuXi XDC, jointly took the stage, officially launching the GMP release of the WuXi XDC Singapore manufacturing site.

Capacity Upgrade to Empower Commercial Manufacturing

The Singapore site serves as a core cornerstone of WuXi XDC's commercial manufacturing, spanning approximately 25,000 square meters. The site's BCM3 dual-function production line and DP4 conjugated drug product facility have both successfully achieved GMP release.

The BCM3 features an efficient and flexible "dual-function" design, offering integrated end-to-end commercial manufacturing services from antibody intermediates to conjugated drug substances. The production line supports batch sizes from 200 L to 2,000 L for antibody intermediates and up to 2,000 L for conjugated drug substances. The line strictly follows international GMP standards such as FDA, EMA, and NMPA, and has established a comprehensive quality control system. In addition, the BCM4 facility is expected to achieve GMP release by the end of 2026, with a maximum single-batch capacity of up to 500 L of conjugated drug substance.

The DP4 facility is equipped with one 10 m² and two 30 m² lyophilizers, providing an annual production capacity of up to 8 million vials of liquid or lyophilized bioconjugates. The facility strictly adheres to GMP standards set by the FDA, EMA and HSA. The core filling line is equipped with a state‑of‑the‑art sterile isolator, enabling 100% in‑line filling weight checking. The filling speed can reach up to 300 vials per minute, with a camera‑based vision system that performs real‑time rejection of vials with missing or high‑seated stoppers. The facility offers comprehensive end-to-end sterile drug product manufacturing and packaging services, covering tools washing and sterilization, compounding, vial washing, depyrogenation, filling, lyophilization, capping, external washing, manual visual inspection, automated visual inspection, labeling, and packaging.

Site Tour Highlights One-Stop Capabilities

After the ceremony, WuXi XDC invited guests to tour the Singapore site. The tour attracted active participation from dozens of MNCs and global biotech companies. The site demonstrated to the industry its integrated end-to-end production capabilities for antibody intermediates, conjugated drug substances, and drug products. The tour covered key production areas of the Singapore site, including production lines, as well as the advanced quality control center and machinery area. Guests highly praised the site's advanced modular design, internationally leading process equipment, and strict quality control system.

The successful GMP release of the WuXi XDC Singapore site is an important milestone in the company's history and solid support for providing end-to-end, one-stop services to more clients worldwide. In the future, the Singapore site will deeply integrate and collaborate with multiple domestic sites to build an integrated, multi-dimensional comprehensive network, continuously empowering partners and the innovative development of the bioconjugate industry.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from clinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

Share this article

Huawei Launches the AI Practice LAB (AIPL) Solution, Setting a New Paradigm for "Education + AI" Talent Cultivation

SHANGHAI, Sept. 21, 2026 /PRNewswire/ -- During HUAWEI CONNECT 2026, the Global Education Summit themed "AI × Education: Building the Talent Foundation for the Digital & Intelligent Era" was successfully held in Shanghai. At the summit, Huawei officially launched the AI Practice LAB (AIPL) Solution globally, and simultaneously released the "AI+ Practical Teaching White Paper" (referred to as the "White Paper").

As AI-driven education transformation gains momentum, the conventional theoretical teaching model can no longer meet the industry's demand for practical capabilities, making AI talent cultivation a top priority for higher education. Drawing on its extensive experience across various industries, Huawei has introduced the AIPL Solution, which is centered around real-world scenarios, real data, and real algorithms. This solution aims to bridge the gap between conventional theoretical teaching and industry needs by introducing real-world industry cases, anonymized data, and engineering tools into teaching practices, helping universities cultivate AI professionals who are truly aligned with industry needs.

Tao Jingwen, Deputy Chairman of the Supervisory Board, Huawei, noted that together with the education sector and industry enterprises, Huawei have integrated AI technology to jointly deepen our exploration of practical education models. We have built "roads" and "bridges" in theoretical learning, practice, and scientific research innovation. Huawei will continue to remain deeply rooted in the education sector, adopting an open approach to collaborate with global universities, research institutions, and industry partners, empowering the digital and intelligent transformation of the education sector through technological innovation.

At the summit, Li Junfeng, Vice President of Huawei and CEO of Global Public Sector BU; Pang Chuanchun, Director of Huawei's Learning & Certification Services Dept; He Lian, Vice President of Wuhan University; Xue Guangtao, Director of Network & Information Center of Shanghai Jiao Tong University jointly launched the Huawei AIPL Solution to the world.

Currently, in collaboration with 12 baseline partners, the solution has been used to build AI practical teaching solutions and has been deployed at multiple universities, including Beijing Institute of Technology and Shanghai Jiao Tong University. This global launch aims to promote the concept and solution of AI practice worldwide, fostering the cultivation of AI innovation talents globally.

At the summit, Huawei, together with multiple universities and partners, released the "AI+ Practical Teaching White Paper". Du Min, President of Huawei Higher Education BU; Sun Gang, Director of Huawei's ICT Talent Partner Development Dept; Zhang Jianjun, Vice President of Huawei; Bi Xiaohan, Deputy Director of UNESCO International Centre for Higher Education Innovation; Xia Zhengwei, Vice Director of Information Center of Wuhan University; Li Kangju, President of the Shenyang Institute of Technology and Lu Jie, Deputy Director of BGI College witnessed the release.

The white paper systematically elaborates the theoretical logic and practical pathways for restructuring higher education talent cultivation paradigms in the AI era. Focusing on the core topic of "AI + practical teaching", it proposes a transformation reference framework featuring "one foundation, two types of elements, three levels of courses, four-dimensional evaluation, and a five-party ecosystem." This framework aims to provide a systematic, pragmatic, and actionable guide for university administrators, frontline teachers, education researchers, and industry professionals.

Looking ahead, Huawei will continue to work closely with universities and partners to strengthen the digital and intelligent foundation of the education industry and promote the replication of the AIPL model across multiple disciplines. By empowering education with technology and cultivating talent through hands-on practice, Huawei will transform cutting-edge industry technologies and real-world business scenarios into educational resources for practical training, smart teaching, smart campus, and research innovation. In this way, high-quality educational resources will be more widely shared.

SOURCE Huawei Technologies Co., Ltd

Share this article

Huawei Unveils New UnifiedBus Computing Architecture for SuperPoDs and Clusters

SHANGHAI, Sept. 21, 2026 /PRNewswire/ -- In a keynote speech on computing architecture innovation at HUAWEI CONNECT 2026, Yang Chaobin, Huawei's Executive Director of the Board and CEO of the ICT Business Group, unveiled new details about the UnifiedBus interconnect architecture, announced a series of computing products based on this architecture, and explained how the company has collaborated with open-source communities to enable application innovation by customers, partners, and developers.

In a traditional computing architecture, resource utilization declines as a cluster scales. As little as 20% of a 100,000-NPU cluster's computing capacity is actually utilized by models, with a vast amount of compute sitting idle during data communications. A 10 trillion-parameter model, which requires massive amounts of intermediate data to train, far exceeds the capacity of the memory on a single accelerator under traditional architectures. Interconnection and communications between components within a cluster have become a key performance bottleneck for computing systems.

According to Yang, Huawei's solution to this bottleneck is its new computing architecture, powered by the interconnect technology called UnifiedBus, which facilitates collaboration between clusters and SuperPoDs. This architecture has been designed to support the boom in compute demand that is emerging as new agentic applications hit the market. UnifiedBus-powered computing systems have four key features:

- Unified protocol and memory semantics: More than ten interconnect protocols have been combined under the UnifiedBus protocol, which increases interconnect bandwidth from 100 GB/s level to TB/s level and reduces round-trip time (RTT) latency from 7 microseconds to 2 microseconds. This protocol also enables unified global memory addressing within SuperPoDs.

- Heterogeneous compute collaboration: UnifiedBus directly interconnects CPUs, NPUs, memory, and solid-state drives (SSDs) to enable decentralized, peer-to-peer access between them and flexible CPU-NPU mixing. In addition, tiered hardware acceleration for Transformer enables Attention-FFN disaggregation (AFD).

- Tiered storage with global pooling: UnifiedBus uses hybrid-media resource pooling to support the caching of activations. Double Data Rate (DDR) memory serves as the alternative memory for NPUs, reducing latency for search, recommendation, and advertising services, and doubling the performance of vector retrieval for 100 billion-level data items with thousands of dimensions. This also reduces the per-NPU HBM capacity requirements for the training of 10 trillion-parameter models, and improves cluster model FLOPs utilization (MFU).

- Optoelectronic interconnect and flexible networking: UnifiedBus serves as a global ultra-high bandwidth, ultra-low latency "data highway", enabling flexible scaling of compute.

Yang then moved on to unveil Huawei's newest UnifiedBus interconnect products that cover interconnection within cabinets, between cabinets, and across clusters. This enables elastic scaling from a single cabinet to a million-NPU cluster.

- Within cabinets, the UnifiedBus LinkBlade eliminates circuit losses with a cable-free design, which reduces copper cabling within a 4,096-NPU SuperPoD by about 196 kilometers.

- Between cabinets, the UnifiedBus LinkDevice supports 176 ports, with 1.6 Tbit/s bandwidth per port, delivering 280 Tbit/s all-optical interconnection. This is the industry's highest-bandwidth, highest-port-count high-speed bus-protocol interconnect device, with an RTT latency as low as 2 microseconds.

- Across clusters, the UnifiedBus UBG switch provides a massive radix fan-out capacity of up to 1,024, meaning it can support a million-NPU SuperCluster and evolution towards supporting tens of trillions of model parameters.

Yang also launched Huawei's UnifiedBus-powered agentic AI SuperCluster, which is comprised of TaiShan 950 and Atlas 960 SuperPoDs, OceanStor M900 memory storage, and a Xinghe UBG switch. This cluster enables diverse compute collaboration and tiered resource pooling.

Beyond SuperPoDs, Huawei has also applied the UnifiedBus technology to its compute appliances. The company has developed a new series of UnifiedBus-based appliances (supporting one to eight NPUs) and Kunpeng and Ascend modules, which enable small and medium-sized enterprises to run trillion-parameter models locally.

On the ecosystem front, Yang said that Ascend is collaborating with open-source frameworks like DeepSeek Harness, OpenCode, and openJiuwen to develop fully open-source intelligent management, inference acceleration, and security framework agent plugins.

Yang promised, "Huawei is committed to innovating at the system level, building a computing-foundation product portfolio, and going open source and open system. We will continue working with customers, partners, and developers to help this ecosystem thrive and offer the world a new option for compute."

SOURCE Huawei Technologies Co., Ltd

Share this article

New results from the SirPAD randomized trial will be presented at VIVA 2026, October 3–6 at Bellagio Las Vegas, focusing on patients with femoropopliteal peripheral artery disease causing intermittent claudication.

LAS VEGAS, Sept. 21, 2026 /PRNewswire/ -- SirPAD randomized 1,252 patients with symptomatic infrainguinal PAD to angioplasty with a MagicTouch sirolimus-coated balloon (Concept Medical) or an uncoated balloon. The main trial, recently published in the New England Journal of Medicine, demonstrated a significant reduction in major adverse limb events with MagicTouch angioplasty at one year. The new analysis of 597 patients treated for femoropopliteal disease without tissue loss will inform on a clinically important population, in whom the goals of revascularization extend beyond limb preservation to include durable symptom relief.

The results will be presented by Prof. Dr. Stefano Barco (Co-PI) as part of the late-breaking clinical trial program at VIVA 2026, one of the leading international meetings dedicated to peripheral vascular disease and endovascular therapy.

About SirPAD Trial

SirPAD Trial is an academic, investigator initiated RCT comparing Sirolimus Coated Balloon (MagicTouch PTA) against uncoated balloon treatment in patients with femoropopliteal or below-the-knee disease. The trial enrolled 1,252 patients with the primary outcome published in the New England Journal of Medicine, indicating that treatment with Sirolimus Coated Balloon arm was both non-inferior and superior against uncoated balloon in terms of MALE.

About Concept Medical

Concept Medical Group develops innovative drug-delivery technologies for coronary and peripheral vascular interventions. The company is the developer of MagicTouch PTA, the sirolimus-coated balloon evaluated in the SirPAD randomized trial.

For more information: www.conceptmedical.com

Share this article

Best UV Protection Sunglasses (2026): Quay Highlighted Among Stylish Options for Everyday Sun Protection by Expert Consumers

NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Expert Consumers has recognized Quay for its approach to everyday sunglasses that combines 100% UV protection with fashion-focused frame designs. The recognition comes as consumers place greater emphasis on eyewear that can provide reliable sun protection without sacrificing style, comfort, or affordability.

Best UV Protection Sunglasses

- Quay - stylish sunglasses with 100% UVA and UVB protection, with multiple sizes, shapes, and lens options for a wide variety of faces.

The search for the best UV protection sunglasses often begins with lens performance. However, frame design, fit, lens technology, and price can also influence the buying decision. Quay's current sunglasses collection addresses these considerations with a broad selection of frame shapes, lens options, and price points.

Strong UV Protection Without Sacrificing Style

UV protection remains one of the most important factors when selecting sunglasses. Quay states that its sunglasses provide 100% UV protection, including UVA and UVB protection across all of its eyewear, including optical and bluelight. The brand offers styles ranging from aviators and cat-eye frames to square, round, oversized, and shield silhouettes.

The distinction between UV protection and lens appearance is important. Darker lenses do not automatically provide greater UV protection. Lens color primarily affects visible light, while UV protection depends on the lens material or protective technology.

Polarized lenses such as the In the City, Soundcheck and Flip Side models represent another consideration. Quay offers polarized options designed to reduce glare, which can be useful around reflective surfaces and during bright outdoor activities. Polarization and UV protection serve different functions, so consumers should check both specifications when evaluating sunglasses.

Frame style can also influence how frequently sunglasses are worn. Quay's collection includes understated designs alongside more prominent silhouettes, giving consumers the ability to prioritize personal style while maintaining UV protection.

100% UV Protection Sunglasses $80 and Under

Price is another practical consideration when searching for the best UV protection sunglasses. Effective UV protection does not necessarily require a high price, but shoppers should verify the protection specifications before purchasing.

Quay currently lists the Nightfall sunglasses at $80, and is available in multiple colors and finishes, including polarized options.

The Nightfall collection demonstrates how an $80 pair can combine a fashion-oriented silhouette with practical lens features. Pricing and availability can change, so current product listings should be checked before purchase.

For consumers shopping within this budget, several factors can help determine whether a pair is suitable for everyday use:

- UV protection: Look for an explicit 100% UVA/UVB or equivalent UV protection specification.

- Fit: Frames should sit securely without creating excessive pressure around the temples or nose.

- Lens coverage: Larger designs can provide broader coverage around the eyes.

- Glare reduction: Polarized lenses can help reduce reflected glare in bright conditions.

- Durability: Materials and construction can influence how well sunglasses hold up to regular use.

This approach puts eye protection ahead of purely cosmetic considerations while still leaving room for personal style.

Can Clear Glasses Block UV Rays?

Clear lenses can provide UV protection. Lens transparency does not determine whether ultraviolet radiation is blocked.

The key consideration is the lens specification. A clear lens can be manufactured with UV-blocking properties, while a dark lens should not be assumed to provide UV protection simply because it appears darker. That said, all of Quay's lenses are manufactured with UV blocking properties.

Current prescription models such as COULD NEVER RX and GAME OVER RX list 100% UVA/UVB protection as part of their lens options. The available prescription lenses include clear options, demonstrating that UV protection and visible lens tint are separate considerations.

For consumers wearing clear glasses outdoors, checking the manufacturer's stated UV protection is more reliable than judging protection by the appearance of the lenses.

Clear eyewear also serves a different purpose from sunglasses. Even when clear lenses provide UV protection, sunglasses can reduce visible brightness and glare, which may make outdoor conditions more comfortable.

Choosing Sunglasses for Everyday Wear

The most useful sunglasses are often the ones that fit naturally into daily routines. Commuting, driving, walking, traveling, exercising, and spending time outdoors can all involve regular exposure to sunlight.

Quay's range includes lightweight frame options and multiple shapes designed for different preferences. Some styles also feature adjustable nose pads, while polarized collections provide an option for consumers who frequently encounter glare.

Prescription wearers can also find selected Quay frames designed for prescription lenses. Current prescription sunglass options include different lens tints and lens materials, depending on the selected frame and prescription requirements.

Fit remains an important consideration. Frame measurements such as lens width, bridge width, temple length, and overall frame width can help consumers compare a new pair with glasses already worn comfortably.

Why Quay Is Gaining Attention in 2026

Expert Consumers' recognition of Quay reflects a broader shift in how consumers evaluate sunglasses. Eye protection remains central, but modern shoppers also expect eyewear to complement personal style and everyday routines.

Quay's current collection combines 100% UV protection with a wide selection of frame shapes and lens treatments. The brand also offers options across different price points, including the currently listed Nightfall style for shoppers seeking 100% UV protection within an $80 budget.

For consumers researching the best UV protection sunglasses, the fundamentals remain straightforward: verify UV protection, consider fit and coverage, evaluate lens features such as polarization, and select a frame that is comfortable enough for regular use.

Quay's approach demonstrates that practical sun protection and contemporary eyewear design can coexist, giving consumers more flexibility when selecting sunglasses for everyday outdoor wear in 2026.

The full article can be viewed at the Expert Consumers website.

About Quay

Quay is a global eyewear brand offering a wide selection of sunglasses and prescription glasses. The company's collections emphasize contemporary design, functional lens features, and pricing that remains accessible to a broad range of consumers. Quay products are available through its direct-to-consumer website, Quay stores and select retail partners worldwide.

About ExpertConsumers.org: Expert Consumers delivers news and insights on consumer products and services. As an affiliate, Expert Consumers may earn commissions from sales generated using links provided.

SOURCE ExpertConsumers.org

Share this article

Grünenthal acquires cancer treatment Stivarga®

- Latest step in Grünenthal's strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth.

- Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma (liver cancer). It is approved and available in more than 90 markets worldwide.

- Grünenthal has invested around €2.6 billion in successful M&A transactions since 2017, significantly strengthening its profitability and further funding its innovative research pipeline.

AACHEN, Germany, Sept. 21, 2026 /PRNewswire/ -- Grünenthal, a global leader in pain management and research, today announced an agreement with Bayer AG to acquire Stivarga®, an oral treatment for specific advanced cancers, for up to €375 million. The acquisition is subject to customary closing conditions, including approval by the relevant regulatory authorities. The acquisition is expected to close by the end of 2026 or early 2027.

Stivarga® (regorafenib) is an oral multkinase inhibitor indicated for metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumours (GIST) in patients who have already been treated with, or who cannot be given, other available treatments. It is approved and available in more than 90 markets worldwide.

"This acquisition is a strong strategic fit for Grünenthal and reflects our disciplined M&A strategy of acquiring established medicines that address clear and ongoing medical needs and create long-term value," said Gabriel Baertschi, CEO, Grünenthal. "Stivarga® has a well-established role in patient care and the transaction is immediately accretive to our business. By leveraging the strength of our commercial and operational expertise, we see clear opportunities to maximise the value of the medicine and support Grünenthal's long-term growth."

Loss of exclusivity for Stivarga® is anticipated in 2029 in the European Union and in 2030 in the United States (US). Grünenthal estimates that Stivarga® may contribute a positive impact on its consolidated EBITDA of up to approximately €100 million for the year ending 31 December 2027, based on an analysis of the information made available to Grünenthal from Bayer and assuming closing by the end of 2026 or the beginning of 2027, as well as a full-year consolidation.

The acquisition is the latest development in Grünenthal's M&A strategy and follows the successful integration of several important medicines across a range of health conditions, including the global rights to Nebido™, the rights to Cialis® in Mexico, Brazil and Colombia, the European rights to Crestor™ and Nexium™, and the global rights to Vimovo™ (ex-US and Japan), Zomig™ (ex-Japan) and Qutenza™. In addition to asset acquisitions, earlier this year, Grünenthal acquired full ownership of Grünenthal Meds, a previously joint venture with Kyowa Kirin International to market its established medicines portfolio, and, in 2024, acquired the US company Valinor Pharma and the product Movantik®. The company has invested around €2.6 billion in successful M&A transactions since 2017.

About Stivarga®

Stivarga® is a once-daily, oral prescription medicine for certain advanced cancers. It has treated more than one million patients across more than 90 countries over 10 years.

In the EU, Stivarga® is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy, as well as for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib, and for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

In the US, Stivarga® is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy, as well as locally advanced, unresectable or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate, and for HCC who have been previously treated with sorafenib.

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion.

More information: www.grunenthal.com

Follow us on LinkedIn & Instagram

Advisors

Freshfields served as legal counsel to Grünenthal.

For further information, please contact:

Matt Crabb, Head of Global Communications (Interim), Grünenthal

[email protected]

SOURCE Grünenthal Group

Share this article

Huawei Releases Intelligent WAN Target Architecture for ISPs

—Fortifying the Connectivity Foundation for ISP AI Services

SHANGHAI, Sept. 21, 2026 /PRNewswire/ -- On September 17, during HUAWEI CONNECT 2026, the roundtable themed "Intelligent WAN, Fortifying the AI Services Connectivity Foundation for ISPs" concluded in Shanghai. The event brought together global ISP experts and partners exploring industry trends, solutions, and best practices. At the roundtable, Huawei unveiled its Intelligent WAN Target Architecture to unlock the potential of AI and computing power in the intelligent era.

Wayne Zhou, Vice President of Huawei's ISP Computing and Network Infrastructure BU, highlighted that AI commercialization is accelerating, enabling asset-heavy players to monetize their capabilities through lightweight services. New trends are reshaping the ISP sector. Moving beyond mere pipelines, ISPs are leveraging edge nodes and their unique advantages to integrate connectivity, computing, and APIs, transitioning from selling bandwidth to delivering AI services. Meanwhile, they are building a unified, intelligent, and service-aware WAN to enhance AI readiness and drive continuous evolution.

Ado, CEO of Huawei's Wide Area Network Domain, introduced the Intelligent WAN Target Architecture. He noted that agentic AI is driving three network shifts: connections shift from humans to agents; traffic patterns shift from heavy downlink traffic to massive uplink traffic; and network experience assurance expands from specific applications to the entire agent workflow. To navigate and leverage these shifts, ISPs must fortify their networks. He proposed prioritizing three strategic pillars: First, building a hierarchical, modular, and standardized IP+Optical converged target architecture. This empowers ISPs to rapidly expand their presence, deliver services, and enhance network resilience, accelerating AI service rollouts. Second, focusing on end-to-end user experience to transform network capabilities into definable, measurable, and deliverable differentiated services. This drives the monetization of both network capabilities and AI. Third, elevating intelligent O&M capabilities. Through tools like Network Digital Map, fault-locating agent, and AI assistant, ISPs can significantly reduce OPEX and improve O&M efficiency. He also proposed an evolution roadmap for target WANs, helping ISPs seize new growth opportunities in the AI era.

At the roundtable, Lintasarta Indonesia, SiliconFlow China and Telconet Ecuador shared their AI services and insights into intelligent network deployment. Participating ISP experts contributed valuable insights, providing actionable guidance for network planning and deployment in the AI era.

Moving forward, Huawei will continue to strengthen its innovation and investment in the ISP and computing network fields, collaborating with customers to usher in a new intelligent future.

Share this article

2026 World Manufacturing Convention Opens in Hefei, Anhui

HEFEI, China, Sept. 21, 2026 /PRNewswire/ -- The 2026 World Manufacturing Convention opened in Hefei, Anhui province, on September 20 under the theme "Intelligent Manufacturing for a Better Future." This is the eighth consecutive year Anhui has hosted the convention. The United Kingdom is the guest country of honor. British Ambassador to China Peter Wilson delivered remarks, while Solange Amicha, representing the Cabinet Minister of the Presidency of Côte d'Ivoire, read out a congratulatory letter from the Ivorian president.

The convention has attracted more than 1,000 guests, including over 500 overseas representatives, and more than 40 overseas companies. The 70,000-square-meter convention features an interactive unmanned-systems showcase at Luogang Park, alongside China-Europe, China-France and China-UK industrial matchmaking events.

The convention secured 735 projects worth 380.2 billion yuan in investment in 2025. During preparations for this year's convention, 946 cooperation projects involving more than 400 billion yuan had been identified, mostly in the ten emerging industries. The convention also continues to engage state-owned, private, foreign-funded, Hong Kong and Macao, Taiwan-funded and overseas Chinese enterprises.

Anhui's manufacturing sector has maintained rapid growth. Revenue from industrial enterprises above designated size has crossed two trillion-yuan thresholds, while the province's manufacturing quality development index has risen from seventh to fifth nationwide. From January to July 2026, value added of industrial enterprises above designated size grew 12.7 percent year on year, the highest in 58 months. Industrial profits rose 63.5 percent to 195.9 billion yuan, contributing 58.3 percent of the province's GDP growth.

In the first seven months, output value of strategic emerging industries grew 17.3 percent, accounting for 46.1 percent of industrial output. New energy vehicle, integrated circuit and robot output rose 27.5 percent, 28.6 percent and 32.8 percent, respectively. Some 17,000 industrial enterprises have completed intelligent and digital transformation. The province now has eight "lighthouse factories" and 1,907 first-set major technical equipment, first-batch new materials and first-version software products.

Anhui will continue developing intelligent connected vehicles, integrated circuits and robotics, while cultivating quantum technology, biomanufacturing and hydrogen energy. It will also advance digital, intelligent and green transformation and build advanced manufacturing clusters worth trillions of yuan.

The convention showcases Anhui's manufacturing achievements and marks a new starting point for deeper integration into global industrial and supply chains.

SOURCE The 2026 World Manufacturing Convention

Share this article